Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 24;17(7):828.
doi: 10.3390/ph17070828.

Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis

Ligang Liu  1 , Hekai Shi  2 , Yufei Shi  3 , Anlin Wang  4 , Nuojin Guo  5 , Heqing Tao  6 , Milap C Nahata  1   7
Affiliations
Review

Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis

Ligang Liu et al. Pharmaceuticals (Basel). .

Abstract

Four glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used in children and adolescents with obesity or overweight. This network meta-analysis was conducted to compare the efficacy and safety of these regimens. Embase, PubMed, and Scopus were searched on March 2023 and updated in June 2024 for eligible randomized controlled trials (RCTs). The primary efficacy outcomes were mean difference in actual body weight, BMI (body mass index), BMI z score, and waist circumference. Safety outcomes included nausea, vomiting, diarrhea, abdominal pain, injection-site reaction, and hypoglycemia. Eleven RCTs with 953 participants were eligible. Semaglutide exhibited greater effects in reducing weight, BMI, and BMI z score versus the placebo. Semaglutide was associated with greater weight loss and BMI z score reduction in comparison with exenatide, liraglutide, and dulaglutide. Semaglutide also significantly decreased BMI than exenatide. None of the four GLP-1 RAs were associated with higher risks of diarrhea, headache, and abdominal pain versus the placebo. Liraglutide was more likely to cause nausea, vomiting, hypoglycemia, and injection-site reactions than the placebo. Liraglutide also had higher odds of causing injection-site reactions than other GLP-1 RAs. Semaglutide appeared to be the most effective and safe option among four GLP-1 RAs in children and adolescents with obesity or overweight.

Keywords: GLP-1RAs; adolescents; efficacy; network meta-analysis; obesity; safety; semaglutide.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study selection process.
Figure 2
Figure 2
Network graphs of each outcome of the main analysis: (a) weight, (b) waist circumference, (c) BMI, (d) BMI z score, (e) HbA1c, (f) DBP, (g) SBP, (h) FPG, (i) insulin, and (j) QOL. Notes: formula image. Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1C; DBP, diastolic blood pressure; SBP, systolic blood pressure; FPG, fasting plasma glucose; QOL, quality of life.
Figure 3
Figure 3
League tables of main outcome analyses. (A) Actual body weight and waist circumference. (B) BMI and BMI z score. The league tables show the relative effects of each medication (the treatment on the column to the treatment of the row). The relative effects are measured as a difference in mean difference (DMD) with a 95% CI for mean change in actual body weight (kg), waist circumference (cm), BMI (kg/m2), and BMI z score. Bold indicates statistical significance. NA: comparison not available.
See this image and copyright information in PMC

References

    1. Skinner A.C., Ravanbakht S.N., Skelton J.A., Perrin E.M., Armstrong S.C. Prevalence of Obesity and Severe Obesity in US Children, 1999–2016. Pediatrics. 2018;141:e20173459. doi: 10.1542/peds.2017-3459. - DOI - PMC - PubMed
    1. Simmonds M., Llewellyn A., Owen C.G., Woolacott N. Predicting adult obesity from childhood obesity: A systematic review and meta-analysis. Obes. Rev. 2016;17:95–107. doi: 10.1111/obr.12334. - DOI - PubMed
    1. Rahmouni K., Correia M.L., Haynes W.G., Mark A.L. Obesity-associated hypertension: New insights into mechanisms. Hypertension. 2005;45:9–14. doi: 10.1161/01.HYP.0000151325.83008.b4. - DOI - PubMed
    1. Shaban Mohamed M.A., AbouKhatwa M.M., Saifullah A.A., Hareez Syahmi M., Mosaad M., Elrggal M.E., Dehele I.S., Elnaem M.H. Risk Factors, Clinical Consequences, Prevention, and Treatment of Childhood Obesity. Children. 2022;9:1975. doi: 10.3390/children9121975. - DOI - PMC - PubMed
    1. Lister N.B., Baur L.A., Felix J.F., Hill A.J., Marcus C., Reinehr T., Summerbell C., Wabitsch M. Child and adolescent obesity. Nat. Rev. Dis. Primers. 2023;9:24. doi: 10.1038/s41572-023-00435-4. - DOI - PubMed

LinkOut - more resources